Skip to main content
Clinical Trials/NCT03991533
NCT03991533
Completed
Not Applicable

Use of Multiparametric Magnetic Resonance Imaging in the Management of Head and Neck Cancer

AZ Sint-Jan AV0 sites30 target enrollmentNovember 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
AZ Sint-Jan AV
Enrollment
30
Primary Endpoint
discriminatory value of MRI D-value
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The investigators aim to identify specific MRI parameters that could improve diagnostic accuracy of metastatic cervical lymph nodes in patients with a squamous cell carcinoma in the head and neck region.

Detailed Description

Background:The locoregional control rates in patients with advanced head and neck cancer remain suboptimal. Accurate diagnosis of metastatic cervical lymph nodes remains challenging. Technological advances in magnetic resonance imaging (MRI) enable to quantify diffusion and perfusion of the tumour and its surrounding tissues, which could improve diagnostic performance. Objectives: The investigators aim to identify specific MRI parameters that could improve diagnostic accuracy of metastatic cervical lymph nodes in patients with a squamous cell carcinoma in the head and neck region. Study design: a retrospective study will be set up to explore the diagnostic performance of the selected MRI parameters to differentiate between tumoural and non-tumoural cervical lymph nodes in patients with a histologically confirmed head and neck tumour ('affected group') or histologically confirmed Whartin tumour or pleomorphic adenoma of the parotid gland, without malignant transformation ('control group'). Patients will be screened for inclusion in the analysis if they had a routine preoperative multiparametric MRI, according to a standardised protocol, between the 1st of December 2016 and the 30th of September 2018. All MR images will be screened by the resident to select those patients with one or multiple clearly distinguishable metastatic cervical lymph node(s), which can be clearly correlated with the final pathology report. Other strict inclusion criteria are described in detail in the protocol.

Registry
clinicaltrials.gov
Start Date
November 1, 2016
End Date
September 2018
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Johan Abeloos

Principal investigator

AZ Sint-Jan AV

Eligibility Criteria

Inclusion Criteria

  • patients that received a pretreatment multiparametric MRI according to a standardized protocol between December 2016 and December 2018
  • histophatologically proven SCC in the head and neck region
  • one or multiple clearly distinguishable cervical lymph node(s), that can be unambiguously correlated with the pathology report

Exclusion Criteria

  • patients not fulfilling abovementioned criteria
  • patients with thyroid or skin cancer
  • considerable artefact on MRI
  • previous surgery, irradiation or chemotherapy in the HN region

Outcomes

Primary Outcomes

discriminatory value of MRI D-value

Time Frame: preoperative

differentiation between a metastatic cervical lymph node and a non-tumoural lymph node, as based on the final pathology report as the 'gold standard'

discriminatory value of MRI perfusion curve

Time Frame: preoperative

differentiation between a metastatic cervical lymph node and a non-tumoural lymph node, as based on the final pathology report as the 'gold standard'

discriminatory value of MRI ADC

Time Frame: preoperative

differentiation between a metastatic cervical lymph node and a non-tumoural lymph node, as based on the final pathology report as the 'gold standard'